Compare RUN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | ARQT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2015 | 2020 |
| Metric | RUN | ARQT |
|---|---|---|
| Price | $12.40 | $24.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 6 |
| Target Price | $19.48 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 7.4M | 1.0M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | 88.79 |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | $376,072,000.00 |
| Revenue This Year | $2.81 | $34.85 |
| Revenue Next Year | $4.54 | $29.39 |
| P/E Ratio | $7.06 | ★ N/A |
| Revenue Growth | 12.97 | ★ 91.34 |
| 52 Week Low | $5.38 | $12.42 |
| 52 Week High | $22.44 | $31.77 |
| Indicator | RUN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 53.77 |
| Support Level | $12.01 | $22.56 |
| Resistance Level | $13.57 | $25.03 |
| Average True Range (ATR) | 0.75 | 0.93 |
| MACD | 0.03 | 0.23 |
| Stochastic Oscillator | 24.26 | 78.05 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.